According to a major international study, Switzerland has once again fallen behind other European countries in terms of access to new innovative medicines – from sixth to seventh place. Particularly worrying is the fact that, compared to Germany, only around half as many new innovative medicines are reimbursed as standard via the specialty list.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Update 2025
Hypercholesterolemia
- GPP: from molecular principles to targeted therapy
Therapeutic rationale for targeted IL-36 receptor inhibition
- HFpEF 2025
Precision medicine and phenotypes
- Myelofibrosis
New treatment options for myelofibrosis patients with a high risk of anemia?
- Chronic insomnia in adults: Guideline recommendations
CBT-i as first choice – pharmacotherapy as secondary intervention
- COPD therapy
Drug therapy – Update 2025
- Pulmonary hypertension
PH and lung diseases
- IBDmatters - Synergy effects for IBD pathways